Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NRIX vs CRMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NRIX Captures Overall Composite Edge (51.5 HOLD vs 53.2 HOLD), While CRMD Leads 4–2 on Growth & Valuation Pillars

NRIX Overall Winner 6-Pillar Tally: NRIX 2 – 4 CRMD Matrix Metrics: NRIX 6 – 4 CRMD

As of Nov 16, 2026, Nurix Therapeutics, Inc. (NRIX) captures the overall head-to-head institutional edge over CorMedix Inc. (CRMD) on higher Unified Composite conviction (51.5/100 HOLD vs. 53.2/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Profitability & Quality), while CRMD wins 4–2 across the 6-pillar growth and valuation breakdown. NRIX trades at $15.01 (N/M Forward P/E, 41.3% operating margin) versus CRMD at $4.92 (49.0x Forward P/E, 41.0% operating margin).

  • Composite vs. Pillar Nuance: While CRMD currently prints a higher short-term Unified Composite Score (53.2/100 HOLD vs. NRIX 51.5/100 HOLD), NRIX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 41.0% operating margin) and revenue trajectory (+8426.3% vs. -47.7% YoY).
  • Technical & Structure Timing Caution: NRIX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NRIX vs CRMD
NRIX NASDAQ Head-to-Head Winner
Nurix Therapeutics, Inc. Common stock
Pharmaceutical Preparations
$15.01
-3.04% 1D
Market Cap $1.7B
TTM Revenue $702M
Forward P/E N/M
Beta / 30D Vol 0.94β · 141% Vol
Unified Composite Score
51.5 / 100 HOLD
Tech 55.0 Fund 58.0 Flow 64.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.1%), weak momentum, RSI 26
RSI-14: 26.2 · SMA20: $21.43 · SMA50: $23.05
CRMD NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap $384.7M
TTM Revenue $1.05B
Forward P/E 49.0x
Beta / 30D Vol 1.20β · 107% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 60.0 Fund 60.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.2%), weak momentum, RSI 29
RSI-14: 29.3 · SMA20: $6.32 · SMA50: $7.11

6-Pillar Scorecard Institutional Category Breakdown (NRIX 2 – 4 CRMD)

Columns: Metric · NRIX · CRMD
1. Valuation Multiples CRMD
Forward P/E N/M 49.0x
Trailing P/E 6.4x 2.4x
PEG Ratio N/M 3.79x
EV / Revenue 1.5x N/M
2. Growth & Scale NRIX
Revenue Growth (YoY) +8426.3% -47.7%
Earnings Growth (YoY) +0.0% +6.7%
TTM Revenue (USD) $702M $1.05B
Market Cap $1.7B $384.7M
3. Profitability & Quality NRIX
Gross Margin 52.4% 87.4%
Operating Margin 41.3% 41.0%
Net Profit Margin 42.0% 15.5%
Return on Equity (ROE) 44.0% 15.3%
4. Balance Sheet & Cash Flow CRMD
Cash Generation (TTM) $370M $785M
Cash Flow Margin 52.7% 74.6%
Net Cash / Leverage $655M Net Cash $535M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRMD
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 79.8% (4th %ile) 56.3% (25th %ile)
Put/Call OI Skew 3.05x (Put-Skewed) 0.69x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat CRMD
OpEx & R&D Intensity 11.1% of Rev ($78M) 46.4% of Rev ($488M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NRIX (6) vs CRMD (4)
Institutional Metric NRIX CRMD Criterion Row Edge
Market Capitalization
Scale
$1.7B $384.7M Larger Scale NRIX
Trailing P/E Ratio
Valuation
6.4x 2.4x Lower Multiple CRMD
Forward P/E Ratio
Valuation
N/M 49.0x Lower Multiple CRMD
Revenue Growth (YoY)
Growth
+8426.3% -47.7% Higher Growth NRIX
Operating Margin (TTM)
Profitability
41.3% 41.0% Higher Margin NRIX
Net Profit Margin
Profitability
42.0% 15.5% Higher Margin NRIX
Return on Equity (ROE)
Capital Efficiency
44.0% 15.3% Higher ROE NRIX
52-Week Range Position
Momentum
18% ($12–$28) 3% ($5–$13) Stronger Trend NRIX
Beta / 30D Volatility
Risk Regime
0.94β · 141% Vol 1.20β · 107% Vol Lower Realized Risk CRMD
Unified Institutional Score
Composite Signal
51.5 / 100 (HOLD) 53.2 / 100 (HOLD) Higher Composite CRMD
Trailing 12M Revenue (USD)
Operating Scale
$702M $1.05B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
52.4% 87.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.5x EV/Rev 3.79x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$370M ($655M Net Cash) $785M ($535M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRMD +6.23 pp
NRIX: -38.53% · CRMD: -32.3%
3M Horizon CRMD +4.42 pp
NRIX: -44.26% · CRMD: -39.84%
6M Horizon NRIX +34.64 pp
NRIX: -3.22% · CRMD: -37.86%
1Y Horizon NRIX +76.92 pp
NRIX: +20.76% · CRMD: -56.16%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NRIX Revenue CRMD Revenue NRIX Op. Margin CRMD Op. Margin Margin Leader
FY2018 N/A $0M N/A -6250.4% CRMD
FY2019 $30M $0M -71.5% -7416.3% NRIX
FY2020 $20M $0M -364.7% -11378.4% NRIX
FY2021 $30M $0M -396.3% -15417.5% NRIX
FY2022 $40M $0M -476.0% -46819.9% NRIX
FY2023 $80M N/A -201.4% N/A NRIX
FY2024 $50M $40M -390.5% -51.4% CRMD
FY2025 $80M $310M -340.2% 48.2% CRMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NRIX BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 79.8%
IV Percentile 4th %ile
Put/Call OI Skew 3.05x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact NRIX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRMD BREAKDOWN
109d in phase · OBV DISTRIBUTION
Current IV 56.3%
IV Percentile 25th %ile
Put/Call OI Skew 0.69x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NRIX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment 11.1% of Rev ($78M)
90D Engineering Disclosures 0 Published
CRMD Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $384.7M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment 46.4% of Rev ($488M)
90D Engineering Disclosures 0 Published

Investor FAQ NRIX vs CRMD Key Questions & Quantitative Answers

As of Nov 16, 2026, Nurix Therapeutics, Inc. (NRIX) captures the overall head-to-head institutional edge over CorMedix Inc. (CRMD) on higher Unified Composite conviction (51.5/100 HOLD vs. 53.2/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Profitability & Quality), while CRMD wins 4–2 across the 6-pillar growth and valuation breakdown. NRIX trades at $15.01 (N/M Forward P/E, 41.3% operating margin) versus CRMD at $4.92 (49.0x Forward P/E, 41.0% operating margin). Composite vs. Pillar Nuance: While CRMD currently prints a higher short-term Unified Composite Score (53.2/100 HOLD vs. NRIX 51.5/100 HOLD), NRIX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 41.0% operating margin) and revenue trajectory (+8426.3% vs. -47.7% YoY). Technical & Structure Timing Caution: NRIX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NRIX leads the Growth & Scale pillar: NRIX posts +8426.3% YoY revenue growth and +0.0% YoY earnings growth on $702M TTM revenue (52.4% gross margin, 41.3% operating margin), compared with CRMD at -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NRIX cumulative revenue shifted +166.7% while CRMD shifted +675.0%. In operating R&D and SG&A reinvestment, NRIX deploys 11.1% of Rev ($78M) (0 90-day corporate R&D disclosures) versus 46.4% of Rev ($488M) (0 disclosures) for CRMD.

CRMD screens cheaper on headline valuation multiples. NRIX trades at N/M Forward P/E, 6.4x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (52.7% FCF margin), whereas CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NRIX (44.0% ROE) versus CRMD (15.3% ROE) capital efficiency.

In options market volatility and institutional positioning, NRIX carries 79.8% implied volatility (4th %ile, Compressed (<25th %ile)), a 3.05x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.94β · 141% Vol realized risk). By comparison, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.